

# L'année 2017

## Le digest du GRDig en 5 min chrono!



## Foie, biliaire



Astrid Lièvre

Service des Maladies de l'Appareil Digestif  
CHU Pontchaillou -Rennes  
Université Rennes 1






# Voies biliaires adjuvant

Enfin un standard en adjuvant !


## BILCAP (ph 3)



## Survie globale



## Survie sans récidence





# Voies biliaires avancé

La médecine de précision: c'est maintenant!




## Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial

Loïc Verlingue <sup>a</sup>, David Malka <sup>b</sup>, Adrien Allorant <sup>c</sup>, Christophe Massard <sup>a</sup>, Charles Ferté <sup>a,b</sup>, Ludovic Lacroix <sup>d,e</sup>, Etienne Rouleau <sup>d,e</sup>, Nathalie Auger <sup>c</sup>, Maud Ngo <sup>a</sup>, Claudio Nicotra <sup>a</sup>, Thierry De Baere <sup>f</sup>, Lambros Tselikas <sup>f</sup>, Bakar Ba <sup>f</sup>, Stefan Michiels <sup>c</sup>, Jean-Yves Scoazec <sup>d,e</sup>, Valérie Boige <sup>b</sup>, Michel Ducreux <sup>b</sup>, Jean-Charles Soria <sup>a,g</sup>, Antoine Hollebecque <sup>a,b,\*</sup>



NGS, CGHa, RNAseq, IHC



No. At Risk	0	6	12	18	24	30	36
Not orientated	20	7	2	1	0	0	0
Targeted treatments	18	15	8	5	3	2	2



# Foie

Un RDV manqué, vivement le prochain?

## Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Helena Pereira, Eric Assenat, Boris Guiu, Alina Diana Ilonca, Georges-Philippe Pageaux, Annie Sibert, Mohamed Bouatour, Rachida Lebtahi, Wassim Allaham, Hélène Barraud, Valérie Laurent, Elodie Mathias, Jean-Pierre Bronowicki, Jean-Pierre Tassu, Rémy Perdriset, Christine Silvain, René Gerolami, Olivier Mundler, Jean-Francois Seitz, Vincent Vidal, Christophe Aubé, Frédéric Oberti, Olivier Couturier, Isabelle Brenot-Rossi, Jean-Luc Raoul, Anthony Sarran, Charlotte Costentin, Emmanuel Itti, Alain Luciani, René Adam, Maité Lewin, Didier Samuel, Maxime Ronot, Aurelia Dinut, Laurent Castera, Gilles Chatellier, on behalf of the SARAH Trial Group\*


- 467 pts, radiembolisation ou sorafenib

## MAIS


...SIRT associée à de meilleurs:

- Tx de réponse: 19% vs 12%; p=0,0421
- Tx de récurrence hépatique
- Tolérance
- Qualité de vie

Idem étude SIRveNIB (Chow ASCO 2017 # 4002)



	0	6	12	18	24	30	36	42	48
<b>Number at risk</b>									
<b>(number censored)</b>									
SIRT	237 (0)	143 (3)	90 (5)	49 (15)	30 (23)	11 (35)	2 (39)	0 (41)	0 (41)
Sorafenib	222 (0)	153 (3)	92 (3)	57 (15)	28 (27)	14 (33)	3 (42)	1 (44)	0 (45)





# Foie



Enfin un standard en 2<sup>ème</sup> ligne!

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

Jordi Bruix, Shukai Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder, René Gerolami, Gianluca Masi, Paul J Ross, Tianqiang Song, Jean-Pierre Bronowicki, Isabelle Ollivier-Hourmand, Masatoshi Kudo, Ann-Li Cheng, Josep M Llovet, Richard S Finn, Marie-Aude LeBerre, Annette Baumhauer, Gerold Meinhardt, Guohong Han, on behalf of the RESORCE Investigators\*



- 573 pts, Child A, regorafenib 160 mg/j 3 sem/4



- Meilleur taux de réponse mRECIST (10,6 vs 4,1%; p<0,005)
- EI grade 3-4: HTA (15%), syndrome main-pied (13%), fatigue (9%), diarrhée (3%)



21  
**HALLYDAY STORY**  
1971



oh ! ma **pauvre** sarah  
il faut boire à la **resorce**



ENCYCLOPÉDIQUE

Merci Johnny!